PMID- 35704113
OWN - NLM
STAT- MEDLINE
DCOM- 20220812
LR  - 20220930
IS  - 1436-3305 (Electronic)
IS  - 1436-3291 (Linking)
VI  - 25
IP  - 5
DP  - 2022 Sep
TI  - Preferred neoadjuvant therapy for gastric and gastroesophageal junction 
      adenocarcinoma: a systematic review and network meta-analysis.
PG  - 982-987
LID - 10.1007/s10120-022-01314-9 [doi]
AB  - INTRODUCTION: Currently, the standard treatment for gastric and gastroesophageal 
      junction (GEJ) adenocarcinoma, including distal esophagus, consists of 
      perioperative chemotherapy (CT) according to FLOT schedule 
      (5FU/leucovorin/oxaliplatin and docetaxel), or of concomitant chemoradiotherapy 
      (CTRT) based on CROSS regimen. However, due to the relatively lack of direct 
      comparisons between perioperative CT and neoadjuvant CTRT, the effectiveness of 
      these new combinations is unknown. Therefore, we performed a network 
      meta-analysis (NMA) to compare the efficacy of different neoadjuvant treatments 
      for gastric and GEJ adenocarcinoma in terms of overall and disease-free survival 
      (OS and DFS). MATERIALS AND METHODS: We searched MEDLINE, Embase, and Cochrane 
      from database inception until February 1st 2022 for randomized clinical trials 
      that enrolled adults with gastric and GEJ carcinomas and provided data about OS 
      and/or DFS. Between-group comparisons were estimated using hazard ratios (HRs) 
      with 95% credible intervals (95% CrIs). Surface under the cumulative rank (SUCRA) 
      curve plots were produced. The primary outcome was OS, secondary endpoint DFS. 
      RESULTS: A total of 1247 citations were screened; 14 randomized clinical trials 
      were included. In Bayesian comparisons, FLOT-based CT ranked as one of the better 
      regimens with a probability of 41%, both with induction CT followed by CTRT 
      (P = 0.45). For DFS analysis, the FLOT regimen was the preferred option 
      (P = 0.62). CONCLUSIONS: In conclusion, this NMA adds further evidence to the 
      optimization of treatment strategies for gastric and GEJ adenocarcinomas and 
      confirms that incorporation of perioperative triplet-based CT improved both OS 
      and DFS compared to surgery alone and other preoperative strategies.
CI  - (c) 2022. The Author(s) under exclusive licence to The International Gastric Cancer 
      Association and The Japanese Gastric Cancer Association.
FAU - Grizzi, Giulia
AU  - Grizzi G
AD  - Oncology Unit, ASST Cremona, Cremona, CR, Italy.
FAU - Petrelli, Fausto
AU  - Petrelli F
AUID- ORCID: 0000-0001-9639-4486
AD  - Oncology Unit, Medical Sciences Department, ASST Bergamo Ovest, Piazzale Ospedale 
      1, 24047, Treviglio, BG, Italy. faupe@libero.it.
FAU - Di Bartolomeo, Maria
AU  - Di Bartolomeo M
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori Di 
      Milano, Milan, MI, Italy.
FAU - Viti, Matteo
AU  - Viti M
AD  - Surgical Oncology Unit, ASST Bergamo Ovest, Treviglio, BG, Italy.
FAU - Texeira Moraes, Mariana
AU  - Texeira Moraes M
AD  - Surgical Oncology Unit, ASST Bergamo Ovest, Treviglio, BG, Italy.
FAU - Luciani, Andrea
AU  - Luciani A
AD  - Oncology Unit, Medical Sciences Department, ASST Bergamo Ovest, Piazzale Ospedale 
      1, 24047, Treviglio, BG, Italy.
FAU - Passalacqua, Rodolfo
AU  - Passalacqua R
AD  - Oncology Unit, ASST Cremona, Cremona, CR, Italy.
FAU - Ghidini, Michele
AU  - Ghidini M
AD  - Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Tomasello, Gianluca
AU  - Tomasello G
AD  - Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Baiocchi, Gian Luca
AU  - Baiocchi GL
AD  - Department of Surgery, ASST Cremona, Cremona, CR, Italy.
FAU - Celotti, Andrea
AU  - Celotti A
AD  - Department of Surgery, ASST Cremona, Cremona, CR, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220615
PL  - Japan
TA  - Gastric Cancer
JT  - Gastric cancer : official journal of the International Gastric Cancer Association 
      and the Japanese Gastric Cancer Association
JID - 100886238
RN  - Adenocarcinoma Of Esophagus
SB  - IM
MH  - *Adenocarcinoma/drug therapy/pathology
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bayes Theorem
MH  - *Esophageal Neoplasms/drug therapy/pathology
MH  - Esophagogastric Junction/pathology
MH  - Humans
MH  - Neoadjuvant Therapy
MH  - Network Meta-Analysis
MH  - *Stomach Neoplasms/drug therapy/pathology
OTO - NOTNLM
OT  - Adenocarcinoma
OT  - Gastric cancer
OT  - Gastroesophageal junction
OT  - Meta-analysis
OT  - Neoadjuvant
OT  - Survival
EDAT- 2022/06/16 06:00
MHDA- 2022/08/13 06:00
CRDT- 2022/06/15 11:16
PHST- 2022/04/20 00:00 [received]
PHST- 2022/05/27 00:00 [accepted]
PHST- 2022/06/16 06:00 [pubmed]
PHST- 2022/08/13 06:00 [medline]
PHST- 2022/06/15 11:16 [entrez]
AID - 10.1007/s10120-022-01314-9 [pii]
AID - 10.1007/s10120-022-01314-9 [doi]
PST - ppublish
SO  - Gastric Cancer. 2022 Sep;25(5):982-987. doi: 10.1007/s10120-022-01314-9. Epub 
      2022 Jun 15.